Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Douglas

Showing results (701-710 of 716) with videos related to

Pageof 72
Sort By:
The Journal of Infectious Diseases|February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
Nature Medicine|December 18, 2020
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Med (New York, N.Y.)|July 5, 2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccinationAngela M Minassian, Sarah E Silk, Jordan R Barrett, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
British Journal of Pharmacology|September 16, 2021
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptorsStephen Ph Alexander, Arthur Christopoulos, Anthony P Davenport, et al.
British Journal of Pharmacology|December 20, 2023
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptorsStephen P H Alexander, Arthur Christopoulos, Anthony P Davenport, et al.
Pageof 72

Showing results (701-710 of 716) with videos related to

Sort By:
Pageof 72
The Journal of Infectious Diseases|February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
Nature Medicine|December 18, 2020
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R Barrett, Sandra Belij-Rammerstorfer, Christina Dold, et al.
Med (New York, N.Y.)|July 5, 2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccinationAngela M Minassian, Sarah E Silk, Jordan R Barrett, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Lancet (London, England)|November 22, 2020
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trialMaheshi N Ramasamy, Angela M Minassian, Katie J Ewer, et al.
Lancet (London, England)|February 22, 2021
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trialsMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
Lancet (London, England)|December 11, 2020
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKMerryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, et al.
British Journal of Pharmacology|September 16, 2021
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptorsStephen Ph Alexander, Arthur Christopoulos, Anthony P Davenport, et al.
British Journal of Pharmacology|December 20, 2023
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptorsStephen P H Alexander, Arthur Christopoulos, Anthony P Davenport, et al.
Pageof 72